Literature DB >> 17111557

ECOG: CHAARTED--ChemoHormonal therapy versus androgen ablation randomized trial for extensive disease in prostate cancer.

Christopher J Sweeney1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17111557

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN： 1543-0790


× No keyword cloud information.
  8 in total

Review 1.  Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies.

Authors:  Cameron M Armstrong; Allen C Gao
Journal:  Am J Clin Exp Urol       Date:  2015-08-08

2.  A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy.

Authors:  A J Armstrong; S Halabi; P Healy; W R Lee; B F Koontz; J W Moul; K Mundy; P Creel; S Wood; K Davis; M A Carducci; M Stein; C Hobbs; B Reimer; M Nguyen; M Anand; L Bratt; S Kim; P T Tran; D J George
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-01-12       Impact factor: 5.554

3.  COOPERATIVE GROUP TRIALS - SOUTHWEST ONCOLOGY GROUP (SWOG) INNOVATIONS IN ADVANCED PROSTATE CANCER.

Authors:  Tanya B Dorff; Cathy M Tangen; E David Crawford; Daniel P Petrylak; Celestia S Higano; Derek Raghavan; David I Quinn; Nicholas J Vogelzang; Ian M Thompson; Maha H A Hussain
Journal:  Ther Adv Med Oncol       Date:  2009       Impact factor: 8.168

4.  Significance of baseline bone markers on disease progression and survival in hormone-sensitive prostate cancer with bone metastasis.

Authors:  Masahiro Nozawa; Isao Hara; Hideyasu Matsuyama; Masayuki Iki; Kazuhiro Nagao; Tsukasa Nishioka; Takahiro Komura; Atsunobu Esa; Shigeya Uejima; Masaaki Imanishi; Yasunari Uekado; Takatoshi Ogawa; Hiroshi Kajikawa; Hirotsugu Uemura
Journal:  World J Urol       Date:  2014-10-30       Impact factor: 4.226

Review 5.  Exploiting synergy: immune-based combinations in the treatment of prostate cancer.

Authors:  Mauricio Burotto; Nishith Singh; Christopher R Heery; James L Gulley; Ravi A Madan
Journal:  Front Oncol       Date:  2014-12-12       Impact factor: 6.244

6.  Adaptive pathways and emerging strategies overcoming treatment resistance in castration resistant prostate cancer.

Authors:  Cameron M Armstrong; Allen C Gao
Journal:  Asian J Urol       Date:  2016-08-22

7.  LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer Therapeutics.

Authors:  Holly M Nguyen; Robert L Vessella; Colm Morrissey; Lisha G Brown; Ilsa M Coleman; Celestia S Higano; Elahe A Mostaghel; Xiaotun Zhang; Lawrence D True; Hung-Ming Lam; Martine Roudier; Paul H Lange; Peter S Nelson; Eva Corey
Journal:  Prostate       Date:  2017-02-03       Impact factor: 4.104

Review 8.  Targeting molecular resistance in castration-resistant prostate cancer.

Authors:  Thenappan Chandrasekar; Joy C Yang; Allen C Gao; Christopher P Evans
Journal:  BMC Med       Date:  2015-09-01       Impact factor: 8.775
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.